{"entity":{"id":"michael-morris","kind":"person","name":"Michael J. Morris","aka":[],"tldr":"Principal investigator of the VISION trial that made lutetium-PSMA a standard prostate cancer treatment.","summary":"Michael J. Morris is Prostate Cancer Section Head on the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. He is a medical oncologist known as principal investigator of the VISION trial, which made lutetium-177 PSMA radioligand therapy a standard prostate cancer treatment, and co-led PSMAfore and PSMA PET studies. His selected papers report lutetium-177 PSMA-617 for metastatic castration-resistant prostate cancer and the PSMAfore comparison against a change of androgen receptor pathway inhibitor in taxane-naive patients. He chaired the Alliance genitourinary committee and focuses on radioligand therapy and imaging biomarkers.","asOf":"2026-09-08","links":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/michael-morris"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morris%20MJ%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["radioligand-therapy","psma-pet"],"targets":["psma"],"drugs":["pluvicto"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["vision","psmafore"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Prostate Cancer Section Head, Genitourinary Oncology Service","institutionId":"mskcc","specialisms":["Prostate cancer","Radiopharmaceuticals","PSMA theranostics"],"profiles":[{"label":"MSK profile","url":"https://www.mskcc.org/cancer-care/doctors/michael-morris"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morris%20MJ%5BAuthor%5D"}],"papers":[{"title":"Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer","journal":"New England Journal of Medicine","year":2021,"url":"https://doi.org/10.1056/NEJMoa2107322","doi":"10.1056/NEJMoa2107322"},{"title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore)","journal":"Lancet","year":2024,"url":"https://doi.org/10.1016/S0140-6736(24)01653-2","doi":"10.1016/S0140-6736(24)01653-2"}]},"route":"/people/michael-morris/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"target":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/"}],"drug":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/"},{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/"}],"paper":[{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/"}]}}